- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01069419
Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)
A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Altenburg, Germany
- 174
-
Amberg, Germany
- 70
-
Attendorn, Germany
- 122
-
Augsburg, Germany
- 153
-
Bad Aibling, Germany
- 3
-
Bad Bramstedt, Germany
- 133
-
Bad Buchau, Germany
- 167
-
Bad Doberan, Germany
- 20
-
Bad Endbach, Germany
- 166
-
Bad Iburg, Germany
- 8
-
Bad Kissingen, Germany
- 66
-
Bad Kreuznach, Germany
- 137
-
Bad Liebenwerda, Germany
- 119
-
Bad Nauheim, Germany
- 4
-
Bad Neuenahr-Ahrweiler, Germany
- 13
-
Bad Staffelstein, Germany
- 87
-
Baden Baden, Germany
- 173
-
Bamberg, Germany
- 19
-
Bautzen, Germany
- 115
-
Bayreuth, Germany
- 21
-
Bayreuth, Germany
- 58
-
Berlin, Germany
- 163
-
Berlin, Germany
- 43
-
Berlin, Germany
- 12
-
Berlin, Germany
- 25
-
Berlin, Germany
- 1
-
Berlin, Germany
- 112
-
Berlin, Germany
- 179
-
Berlin, Germany
- 26
-
Berlin, Germany
- 54
-
Berlin, Germany
- 59
-
Berlin, Germany
- 61
-
Berlin, Germany
- 72
-
Berlin, Germany
- 78
-
Berlin, Germany
- 91
-
Berlin, Germany
- 95
-
Chemnitz, Germany
- 28
-
Chemnitz, Germany
- 75
-
Darmstadt, Germany
- 134
-
Darmstadt, Germany
- 71
-
Deggendorf, Germany
- 125
-
Dresden, Germany
- 131
-
Dresden, Germany
- 36
-
Dresden, Germany
- 88
-
Dresden, Germany
- 98
-
Duisburg, Germany
- 49
-
Düsseldorf, Germany
- 46
-
Elmshorn, Germany
- 102
-
Erfurt, Germany
- 83
-
Erlangen, Germany
- 2
-
Essen, Germany
- 37
-
Essen, Germany
- 84
-
Frankenberg-Sachsen, Germany
- 136
-
Frankfurt, Germany
- 103
-
Frankfurt, Germany
- 53
-
Freiberg, Germany
- 29
-
Freiburg, Germany
- 86
-
Fulda, Germany
- 77
-
Goslar, Germany
- 15
-
Greifswald, Germany
- 135
-
Gräfelfing, Germany
- 89
-
Guestrow, Germany
- 107
-
Göttingen, Germany
- 100
-
Hagen, Germany
- 157
-
Haldensleben, Germany
- 150
-
Halle, Germany
- 11
-
Hamburg, Germany
- 116
-
Hamburg, Germany
- 128
-
Hamburg, Germany
- 139
-
Hamburg, Germany
- 175
-
Hamburg, Germany
- 50
-
Hamburg, Germany
- 55
-
Hamburg, Germany
- 67
-
Hamburg, Germany
- 6
-
Hanau, Germany
- 129
-
Hannover, Germany
- 159
-
Hannover, Germany
- 171
-
Hannover, Germany
- 17
-
Heidelberg, Germany
- 138
-
Heidelberg, Germany
- 146
-
Heidelberg, Germany
- 47
-
Heilbad Heiligenstadt, Germany
- 92
-
Herrsching, Germany
- 64
-
Hildesheim, Germany
- 5
-
Hofheim, Germany
- 30
-
Hoyerswerda, Germany
- 48
-
Karlsruhe, Germany
- 130
-
Karlsruhe, Germany
- 56
-
Karlsruhe, Germany
- 96
-
Karlstadt, Germany
- 101
-
Kassel, Germany
- 121
-
Katzhuette, Germany
- 161
-
Kiel, Germany
- 158
-
Köln, Germany
- 16
-
Köln, Germany
- 73
-
Köln, Germany
- 97
-
Leipzig, Germany
- 127
-
Ludwigsfelde, Germany
- 51
-
Ludwigslust, Germany
- 140
-
Lübeck, Germany
- 93
-
Magdeburg, Germany
- 68
-
Mainz, Germany
- 145
-
Marktredwitz, Germany
- 31
-
Mittelherwigsdorf, Germany
- 94
-
Mönchengladbach, Germany
- 18
-
Mühlheim an der Ruhr, Germany
- 104
-
München, Germany
- 10
-
München, Germany
- 164
-
München, Germany
- 178
-
München, Germany
- 9
-
Münster, Germany
- 113
-
Münster, Germany
- 123
-
Naunhof, Germany
- 57
-
Neubrandenburg, Germany
- 32
-
Neuburg, Germany
- 108
-
Neuruppin, Germany
- 149
-
Neuss, Germany
- 44
-
Nienburg, Germany
- 7
-
Norderstedt, Germany
- 141
-
Nürnberg, Germany
- 172
-
Nürnberg, Germany
- 22
-
Oberammergau, Germany
- 99
-
Oberhausen, Germany
- 23
-
Offenburg, Germany
- 33
-
Osnabrück, Germany
- 38
-
Paderborn, Germany
- 154
-
Pirna, Germany
- 34
-
Planegg, Germany
- 81
-
Plauen, Germany
- 85
-
Potsdam, Germany
- 27
-
Potsdam, Germany
- 35
-
Ratingen, Germany
- 24
-
Rendsburg, Germany
- 82
-
Rheine, Germany
- 124
-
Rostock, Germany
- 109
-
Rostock, Germany
- 76
-
Rüdersdorf, Germany
- 90
-
Saarbrücken, Germany
- 39
-
Salzwedel, Germany
- 69
-
Schramberg-Sulgen, Germany
- 117
-
Schwerin, Germany
- 143
-
Schwerte, Germany
- 142
-
Seesen, Germany
- 120
-
Stadtbergen, Germany
- 105
-
Stuttgart, Germany
- 14
-
Stuttgart, Germany
- 40
-
Traunstein, Germany
- 160
-
Treuenbrietzen, Germany
- 170
-
Tübingen, Germany
- 41
-
Uffenheim, Germany
- 168
-
Ulm, Germany
- 111
-
Ulm, Germany
- 65
-
Villingen-Schwenningen, Germany
- 52
-
Weener, Germany
- 106
-
Weiden, Germany
- 162
-
Weißenfels, Germany
- 177
-
Wiesbaden, Germany
- 118
-
Wiesbaden, Germany
- 74
-
Winsen, Germany
- 60
-
Würselen, Germany
- 165
-
Würzburg, Germany
- 152
-
Zeven, Germany
- 110
-
Zwiesel, Germany
- 45
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients eligible for treatment with Cimzia as defined in EU approved SmPC
Exclusion Criteria:
- Patient previously treated with Cimzia. Patient with known hypersensitivity to any component of Cimzia
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Cimzia
All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Remission at Visit 9 (Around Week 104) Measured by Achieving a Disease Activity Score 28 (DAS28) of < 2.6
Time Frame: From Baseline to Visit 9 (around Week 104)
|
The DAS28 was calculated using the tender and swollen joint counts, c-reactive Protein (CRP), or erythrocyte sedimentation rate (ESR), and the Patient's Global Assessment of Disease Activity (PtGADA). The joint assessment was carried out on 28 joints. For the analysis, DAS28 values were categorized into the following groups:
|
From Baseline to Visit 9 (around Week 104)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Visit 9 (Around Week 104) in Patients's Arthritis Pain as Measured by Patient's Assessment of Arthritis Pain (PAAP) Visual Analog Scale (VAS)
Time Frame: From Baseline to Visit 9 (around Week 104)
|
Patients rated how much pain they were experiencing at the time of the visit caused by their Arthritis using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 100 (most severe pain).
A negative value in Change from Baseline indicates an improvement from Baseline to Visit 9 (around Week 104).
|
From Baseline to Visit 9 (around Week 104)
|
Change From Baseline to Visit 9 (Around Week 104) in Patient's Physical Function as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time Frame: From Baseline to Visit 9 (around Week 104)
|
The HAQ-DI contains 20 items on a 4-point scale ranging from 0 (without any difficulty) to 3 (unable to do).
The 20 items are grouped in 8 categories with 2 to 3 items each.
The category scores are averaged into an overall HAQ-DI from 0 to 3. Scores of 0 to 1 generally represent mild to moderate difficulty, 1 to 2 represent moderate to severe disability, and 2 to 3 indicate severe to very severe disability.
A negative value in Change from Baseline indicates an improvement from Baseline to Visit 9 (around Week 104).
|
From Baseline to Visit 9 (around Week 104)
|
Change From Baseline to Visit 9 (Around Week 104) in Disease Activity Measured by Clinical Disease Activity Index (CDAI)
Time Frame: From Baseline to Visit 9 (around Week 104)
|
The CDAI was calculated with the equation: CDAI= Tender Joint Count + Swollen Joint Count + PtGADA/10 + PhGADA/10 where PtGADA (mm) is the Patient's Global Assessment of Disease Activity using a Visual Analog Scale (VAS) ranging from 0 to 100, and PhGADA (mm) is the Physician's Global Assessment of Disease Activity using a VAS ranging from 0 to 100. Thus, the CDAI ranges from 0 to 76, with higher values indicating higher disease activity. If any individual term was missing, then the CDAI was set to missing. A negative value in Change from Baseline indicates an improvement from Baseline to Visit 9 (around Week 104). |
From Baseline to Visit 9 (around Week 104)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RA0027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar